← ANALYST RATINGS · TIPRANKS
Kiniksa Pharmaceuticals (KNSA): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $96.57, the highest $107, the lowest $87.00. The average is +22.9% from the last price of $78.59.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $100 | Buy | +27.2% | Reiterated | 15.10.26on TipRanks 07:50 | +1.1%next day −0.6% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $87.00 | Buy | +10.7% | Reiterated | 29.09.26on TipRanks Sep 30 05:30 | −0.3%next day −1.3% · 5 days −0.2% | ↗ |
| AI PerPlexity Medical - PharmaceuticalsPerPlexity SonarPro | TipRanks - PerPlexity | $92.00 → $94.00+2.2% | Buy | +19.6% | Reiterated | 20.08.26on TipRanks 01:05 | — | |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $98.00 | Buy | +24.7% | Reiterated | 12.08.26on TipRanks Aug 13 08:40 | +0.2%next day −1.1% · 5 days +3.8% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $75.00 → $90.00+20.0% | Buy | +14.5% | Reiterated | 30.07.26on TipRanks 06:20 | −5.0%next day −5.7% · 5 days −5.8% | ↗ |
| AI xAi Medical - PharmaceuticalsxAI Grok-3 | TipRanks - xAI | $72.00 → $93.00+29.2% | Buy | +18.3% | Reiterated | 29.07.26on TipRanks 10:44 | — | |
| AI Anthropic Medical - PharmaceuticalsAnthropic Opus-4.6 | TipRanks - Anthropic | $70.00 → $88.00+25.7% | Buy | +12.0% | Reiterated | 29.07.26on TipRanks 10:44 | — | |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $72.00 → $107+48.6% | Buy | +36.1% | Assigned | 29.07.26on TipRanks 08:18 | +3.4%next day −5.0% · 5 days −9.0% | ↗ |
| AI Google Medical - PharmaceuticalsGemini 3-pro | TipRanks - Google | $74.00 → $93.00+25.7% | Buy | +18.3% | Reiterated | 29.07.26on TipRanks 06:06 | — | |
| AI DeepSeek Medical - PharmaceuticalsDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $74.00 → $93.00+25.7% | Buy | +18.3% | Reiterated | 29.07.26on TipRanks 06:06 | — | |
| AI OpenAI Medical - PharmaceuticalsOpenAI 5.2 | TipRanks - OpenAI | $73.00 → $92.00+26.0% | Buy | +17.1% | Reiterated | 29.07.26on TipRanks 06:06 | — | |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $72.00 → $99.00+37.5% | Buy | +26.0% | Reiterated | 28.07.26on TipRanks Jul 29 09:08 | +24.8%next day +3.4% · 5 days −8.5% | ↗ |
| Nicholas Lorusso★★★★★★★★★★#2971 · hits 56% · avg +39.7% | TD Cowen | $65.00 → $95.00+46.2% | Buy | +20.9% | Reiterated | 28.07.26on TipRanks 11:51 | +24.8%next day +3.4% · 5 days −8.5% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $58.00 → $71.00+22.4% | Buy | −9.7% | Reiterated | 28.04.26on TipRanks 13:10 | +24.0%next day −1.6% · 5 days +3.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Kiniksa Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $96.57 at a price of $74.61 (+29.4%); now: $96.57 at $78.59 (+22.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 10 | 10 | 11 | 11 | 11 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.37 (from $0.28 to $0.53). Last quarter: $0.30.
Sales
Next quarter’s sales estimate — $260M (from $258M to $265M). Last quarter: $244M.
Best top-analyst consensus in the sector · Healthcare
About Kiniksa Pharmaceuticals
- CEO: Sanj K. Patel
- Employees: 366
- 105 Piccadilly, London, GL, W1J 7NJ, GB
- www.kiniksa.com
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Data from the stock’s TipRanks forecast page, read 31 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗